Amgen (NASDAQ:AMGN) Issues FY 2026 Earnings Guidance

Amgen (NASDAQ:AMGN) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 21.600-23.000 for the period, compared to the consensus EPS estimate of 22.020. The company issued revenue guidance of $37.0 billion-$38.4 billion, compared to the consensus revenue estimate of $37.0 billion.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AMGN. Cantor Fitzgerald boosted their price objective on Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. BMO Capital Markets upped their price target on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Monday, December 15th. Guggenheim raised their price objective on shares of Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Finally, Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target for the company. in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus price target of $342.45.

Amgen Stock Down 1.8%

Amgen stock traded down $6.09 during trading hours on Tuesday, reaching $338.59. The stock had a trading volume of 4,023,196 shares, compared to its average volume of 2,766,270. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The company has a market cap of $182.32 billion, a price-to-earnings ratio of 26.17, a PEG ratio of 3.02 and a beta of 0.46. Amgen has a 52 week low of $261.43 and a 52 week high of $353.25. The business’s 50 day moving average price is $332.81 and its 200-day moving average price is $309.74.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.74 by $0.55. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts anticipate that Amgen will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is 73.57%.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares in the company, valued at $2,381,251.68. The trade was a 11.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 10,908 shares of company stock worth $3,674,966. Corporate insiders own 0.69% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 beat — Amgen reported EPS $5.29 vs. $4.74 consensus and revenue $9.87B vs. $9.46B; management cited higher drug sales and a lower tax rate as drivers. Amgen quarterly results beat Street estimates
• Positive Sentiment: Company releases — Full press release and investor slide deck available detailing results and product updates, useful for modeling near-term revenue and margin drivers. Amgen press release
• Positive Sentiment: Positive market commentary — Jim Cramer highlighted Amgen’s strong pipeline following JPMorgan Healthcare takeaways, which can support investor confidence in growth prospects. Jim Cramer on Amgen
• Neutral Sentiment: Wall Street coverage — Recent pieces assess whether analysts remain bullish or bearish; watch for updated analyst commentary and any changes to guidance or model assumptions. Amgen Stock: Is Wall Street Bullish or Bearish?
• Neutral Sentiment: MariTide focus — Analyst previews note that progress on MariTide and other pipeline milestones will be keys for investors going forward. Amgen Q4 preview
• Neutral Sentiment: Market data oddity — Reported short-interest update shows implausible zero figures (likely data error); not a meaningful market signal.
• Negative Sentiment: Collaboration setback — Amgen ended its Kyowa Kirin collaboration on rocatinlimab; analysts are reassessing valuation and potential future revenue from that program, which may be weighing on the stock. Assessing Amgen valuation after ending Kyowa Kirin collaboration

Institutional Trading of Amgen

Several institutional investors have recently added to or reduced their stakes in AMGN. Brighton Jones LLC raised its holdings in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Schnieders Capital Management LLC. lifted its holdings in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after buying an additional 114 shares during the period. American Trust purchased a new stake in Amgen during the third quarter valued at about $243,000. Finally, Clark Capital Management Group Inc. increased its stake in Amgen by 19.8% during the third quarter. Clark Capital Management Group Inc. now owns 1,103 shares of the medical research company’s stock worth $311,000 after acquiring an additional 182 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.